The U.S. has approved BioLineRx’s Aphexda (motixafortide) in combination with filgrastim (G-CSF) to improve the process of autologous hematopoietic stem cell transplant (AHSCT) for people with multiple myeloma. AHSCT’s success depends on efficacious mobilization of healthy blood stem cells into the bloodstream for collection and subsequent transplant.
Some multiple myeloma cells acquire mutations that allow them to act in disguise and to escape the effects of T-cell therapies, according to a study that calls for the screening of patients for these mutations for better disease management. “Recognizing these mutations and gaining a clearer understanding of the…
Blood Cancer Awareness Month, observed globally every September, seeks to raise awareness of all blood malignancies — there’s one case of blood cancer diagnosed every three minutes in the U.S. alone — with advocacy and research groups launching new campaigns each year. For its part, the International Myeloma…
The U.S. Food and Drug Administration (FDA) has granted conditional approval to Pfizer‘s elranatamab — an antibody therapy to be marketed under the brand name Elrexfio — for adults with difficult-to-treat multiple myeloma. Eligible patients will have received at least four prior lines of therapy, including a…
Nanjing Leads Biolabs is planning to launch a first-in-human clinical trial to test LBL-034, an antibody-based therapy designed to trigger the immune system to destroy cancer cells, in people with relapsed or refractory multiple myeloma in the U.S. and China. Leads Biolabs has received approval to launch the…
Researchers at Tel Aviv University in Israel have developed a new nanoparticle system that can deliver RNA-based therapies designed to kill myeloma cells in bone marrow. Nanoparticle-mediated delivery of an RNA therapy specifically designed to reduce levels of CKAP5 — a protein required for cancer cells to grow and…
A European Medicines Agency committee has recommended that one antibody-based cancer therapy from Janssen Pharmaceuticals be approved for the treatment of relapsed and refractory multiple myeloma (RRMM), and that a second — one already with approval in the European Union for RRMM — be cleared for a less-frequent…
The International Myeloma Foundation (IMF) will host its second in-person Patient and Family Seminar of the year on Aug. 18-19 in Los Angeles. At the upcoming event, which will be held at the Sofitel Hotel in the Southern California city and livestreamed, individuals with this rare cancer…
Multiple myeloma patients undergoing a stem cell transplant in an outpatient setting spent about a week less in the hospital than those undergoing the procedure in an inpatient setting, a new study demonstrated. Data also showed that outpatient transplant — which does not require the patient to be hospitalized…
The U.S. Food and Drug Administration (FDA) has placed a hold on clinical testing of CART-ddBCMA, a cell therapy that Arcellx and Kite Pharma are co-developing for people with relapsed and refractory multiple myeloma (rrMM), following the death of a patient enrolled in the trial. The move pauses the…
Get regular updates to your inbox.